We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ADC Synthesis in Flow

Video   Oct 06, 2016

 

The use of continuous flow technology for the synthesis of protein bioconjugates will be presented. In addition to reagent proteins, monoclonal antibody conjugates will also be highlighted.

 
Company Information

Request Information

 
 
 

Recommended Videos

ADDomer – A New Kind of Vaccine for Untreatable Infection

Video

Scientists from the University of Bristol, CNRS and Imophoron Ltd worked with the computer technology giant Oracle to develop a new kind of vaccine that needs no refrigeration. They used synthetic biology, cryo-electron microscopy and high-performance cloud computing to produce a candidate vaccine against the mosquito-borne chikungunya virus. Their findings could revolutionise the way vaccines are designed, developed and stored.

WATCH NOW

Monoclonal Antibodies: Making Cancer a Target

Video

Monoclonal antibodies, like the drugs Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxin (rituximab), are effective in treating a wide range of cancer types such as lung cancer, breast cancer, lymphoma, and others. By binding to cancer antigens, monoclonal antibodies mark the cells for destruction by the immune system. Clinical trials of more monoclonal antibodies for additional cancer types are ongoing.

WATCH NOW

Nerve Repair: Regeneration in Spinal-cord Injury

Video

Spinal-cord injuries affect about half a million people each year and can leave patients completely paralysed below the site of injury. Currently, damage to this precious bundle of nerve fibres is irreversible. Researchers are working to understand why the nerves of the central nervous system fail to repair themselves, in the hope of finding ways to reboot the regeneration process.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE